User contributions
For
(newest | oldest) View (newer 20 | older 20) (20 | 50 | 100 | 250 | 500)
- 16:10, 13 November 2017 (diff | hist) . . (+1,106) . . MMP-9
- 16:04, 13 November 2017 (diff | hist) . . (+1,267) . . MMP-9
- 15:49, 13 November 2017 (diff | hist) . . (+1,813) . . N MMP-9 (Created page with "Key concepts in ALS == Inhibition == ''Ischemic stroke is a leading cause of disability worldwide. In cerebral ischemia there is an enhanced expression of matrix metallo...")
- 14:55, 13 November 2017 (diff | hist) . . (+24) . . Sulforaphane
- 10:23, 13 November 2017 (diff | hist) . . (+40) . . Plan for an Integral Clinical Trial
- 10:17, 13 November 2017 (diff | hist) . . (+118) . . Plan for an Integral Clinical Trial
- 10:08, 13 November 2017 (diff | hist) . . (+138) . . Plan for an Integral Clinical Trial
- 10:01, 13 November 2017 (diff | hist) . . (+8) . . Sulforaphane
- 16:19, 12 November 2017 (diff | hist) . . (+8) . . Sulforaphane
- 16:15, 12 November 2017 (diff | hist) . . (+20) . . Sulforaphane
- 15:56, 12 November 2017 (diff | hist) . . (0) . . Nrf2 (current)
- 15:55, 12 November 2017 (diff | hist) . . (+6) . . Nrf2
- 15:51, 12 November 2017 (diff | hist) . . (+2,929) . . Nrf2
- 15:49, 12 November 2017 (diff | hist) . . (-2,928) . . Sulforaphane
- 15:47, 12 November 2017 (diff | hist) . . (-1,581) . . Sulforaphane
- 15:43, 12 November 2017 (diff | hist) . . (-1,317) . . Sulforaphane
- 15:42, 12 November 2017 (diff | hist) . . (+4) . . Sulforaphane
- 15:39, 12 November 2017 (diff | hist) . . (+21) . . Key concepts in ALS
- 15:37, 12 November 2017 (diff | hist) . . (0) . . Nrf2
- 15:36, 12 November 2017 (diff | hist) . . (+6) . . Nrf2
(newest | oldest) View (newer 20 | older 20) (20 | 50 | 100 | 250 | 500)